[1] Osorio M, Moubayed SP, Su H, et al.  Systematic review of site distribution of bone metastases in differentiated thyroid cancer[J]. Head Neck, 2017, 39(4): 812-818.   doi: 10.1002/hed.24655
[2] Nakayama R, Horiuchi K, Susa M, et al.  Clinical outcome after bone metastasis (BM) surgery in patients with differentiated thyroid carcinoma (DTC): a retrospective study of 40 cases[J]. Jpn J Clin Oncol, 2014, 44(10): 918-925.   doi: 10.1093/jjco/hyu099
[3] Muresan MM, Olivier P, Leclère J, et al.  Bone metastases from differentiated thyroid carcinoma[J]. Endocr Relat Cancer, 2008, 15(1): 37-49.   doi: 10.1677/ERC-07-0229
[4] Sobrinho-Simões M, Eloy C, Magalhães J, et al.  Follicular thyroid carcinoma[J]. Mod Pathol, 2011, 24 Suppl 2: S10-18.   doi: 10.1038/modpathol.2010.133
[5] 寇天雷, 李杰.  以骨转移为首发症状的甲状腺滤泡癌病理特征分析[J]. 解放军医学院学报, 2015, 36(2): 130-132.   doi: 10.3969/j.issn.2095-5227.2015.02.010
Kou TL, Li J.  Pathological features of follicular thyroid carcinoma with bone metastasis as the first symptom[J]. Acad J Chin PLA Med Sch, 2015, 36(2): 130-132.   doi: 10.3969/j.issn.2095-5227.2015.02.010
[6] 王秋, 王治国, 张国旭, 等.  碘131治疗69例分化型甲状腺癌的临床观察[J]. 辽宁医学杂志, 2015, 29(1): 55-56.
Wang Q, Wang ZG, Zhang GX, et al.  Clinical observation of iodine 131 in the treatment of 69 patients with differentiated thyroid cancer[J]. Med J Liaoning, 2015, 29(1): 55-56.
[7] Benua RS, Cicale NR, Sonenberg M, et al.  The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer[J]. Am J Roentgenol Radium Ther Nucl Med, 1962, 87: 171-182.
[8] Thies ED, Tanase K, Maeder U, et al.  The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma[J]. Eur J Nucl Med Mol Imaging, 2014, 41(12): 2281-2290.   doi: 10.1007/s00259-014-2851-2